lifestyle.californiaconsumerbanking.com

Author: DECHRA PHARMACEUTICALS LIMITED

Dechra Announces FDA Approval of CosACTHen® (cosyntropin injection), the First and Only Cosyntropin Approved Specifically for Canine Patients

May 19, 2026
Dechra to Establish Global Headquarters in Boston, Strengthening U.S. Leadership and Innovation Presence

May 1, 2026
Dechra Announces Veterinary Oral Health Council (VOHC®) Acceptance of VETRADENT® Dental Wipes for Dogs, Recognizing Proven Tartar Control Performance

April 29, 2026